Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Sponsor: National Cancer Institute (NCI)
A PHASE3 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 57 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
57 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Mar 2025 — Jun 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 52 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .